Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding, Janssen said Monday in a press release.
The Janssen Pharmaceutical Companies of Johnson & Johnson got the FDA’s Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of #respiratory syncytial virus (RSV)- mediated lower respiratory tract disease in adults aged 60 years or older. @JNJNews
Allergan plc announced on Friday that it has launched a generic version of Janssen’s Invega (paliperidone extended-release tablets) in the…
Johnson & Johnson has Announced BARDA Funding Award to Accelerate Ebola Vaccine Program Prime-boost vaccine regimen in development at the…